Medicortex Finland Oy ⚠ Under review

About

Funding history · 1 round · $540K total

Offices

Q&A

What is Medicortex Finland Oy's primary focus?

Medicortex Finland Oy is a biotechnology company focused on developing diagnostic and treatment tools for neurodegenerative conditions, particularly traumatic brain injury (TBI).

When was Medicortex Finland Oy founded?

Medicortex Finland Oy was founded in 2014.

What is Medicortex Finland Oy's main product development area?

Medicortex Finland Oy is developing a novel biomarker-based diagnostic test for traumatic brain injuries (TBI) that is rapid and non-invasive, using body fluids like urine and saliva.

Has Medicortex Finland Oy raised any funding through an IPO?

Yes, Medicortex Finland Oy completed an IPO in September 2021, raising $540,000. The lead investors were Dividend Sweden AB and Existing shareholders.

Who is the CEO and founder of Medicortex Finland Oy?

Adrian Harel is the Chief Executive Officer (CEO) and founder of Medicortex Finland Oy, appointed in 2014.

Who is the current Chief Operating Officer (COO) of Medicortex Finland Oy?

Pihla Miettinen was appointed as the Chief Operating Officer (COO) of Medicortex Finland Oy in 2023.

What is Medicortex Finland Oy's drug development program focused on?

Medicortex Finland Oy has a drug development program aimed at preventing the progression and aggravation of traumatic brain injury.

What are the primary target markets for Medicortex Finland Oy's technology?

Medicortex Finland Oy's primary target markets include Traumatic Brain Injury Diagnostics and Stroke Diagnostics.

Sectors & technology